Syneos acquires consulting firm to boost regulatory, safety, pharmacovigilance capabilities

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/NicoElNino)
(Image: Getty/NicoElNino)

Related tags: Syneos Health, Regulation, Safety, Pharmacovigilance, Commercialization

Syneos Health has acquired the UK-based advisory firm Kinapse in a deal that will double its consulting footprint in Europe and further strengthen its commercial offerings – one company's fastest-growing lines of business, says CEO.

Established in 2005, Kinapse provides services across clinical and commercial development. According to Syneos​, Kinapse’s capabilities will expand its post-market regulatory, safety, and pharmacovigilance consulting and operations.

The deal also bolsters Syneos’ clinical trial transparency, medical writing and quality operations and consulting capabilities in R&D and clinical operations, medical affairs, market access, and quality and compliance.

Additionally, the UK-headquartered company has more than 600 staff located in Europe, India, and the US – increasing Syneos’ capabilities in Asia Pacific and doubling its consulting footprint in Europe.

Kinapse operations will be integrated into Syneos’ consulting business.

Read more: Commercial Trends Forecast: ‘R&D is transforming into R&D&C’

The acquisition – terms of which were not disclosed – was funded through cash on hand.

As part of the announcement, Syneos reaffirmed its 2018 guidance range provided​ earlier this month. Also on the second quarter earnings call​, Syneos CEO Alistair Macdonald said the company’s commercial strategy consulting services represents one of its fastest-growing lines of business.

The company reported total net awards of $1.1bn, which included multiple new strategic relationships, driven by collaboration and cross-selling across the clinical and commercial organizations, he said.

Regarding the Kinapse acquisition, Macdonald said the company is “poised to further strengthen”​ its commercial business by integrating Kinapse’s services into “more comprehensive offerings.”

“As customers increasingly face risk, competition and rising development costs, the innovative, technology-enabled solutions provided by Kinapse are seeing increasing demand,”​ he said in a press release.

Syneos is not providing any further comment at this time.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars